PMID- 33660412
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20220107
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Print)
IS  - 1930-7381 (Linking)
VI  - 29
IP  - 4
DP  - 2021 Apr
TI  - Bingeing on High-Fat Food Enhances Evoked Dopamine Release and Reduces Dopamine 
      Uptake in the Nucleus Accumbens.
PG  - 721-730
LID - 10.1002/oby.23122 [doi]
AB  - OBJECTIVE: Binge-eating disorder (BED) disrupts dopamine neuron function, in part 
      by altering dopamine transporter (DAT) activity. This study characterized the 
      effects of high-fat bingeing on presynaptic dopamine terminals and tested the 
      hypothesis that acute low-dose amphetamine would restore DAT function. METHODS: 
      C57BL/6 mice were given limited access (LimA) to a high-fat diet (2 h/d, 3 d/wk) 
      or standard chow (control). After 6 weeks, ex vivo fast-scan cyclic voltammetry 
      was used to characterize dopamine-terminal adaptations in the nucleus accumbens. 
      Prior to undergoing fast-scan cyclic voltammetry, some mice from each group were 
      given amphetamine (0.5 mg/kg intraperitoneally). RESULTS: Escalation of high fat 
      intake, termed bingeing, occurred in the LimA group and coincided with increased 
      phasic dopamine release, reduced dopamine uptake rates, and increased dopamine 
      receptor 2 (D(2) ) autoreceptor function. Acute amphetamine selectively reversed 
      dopamine uptake changes in the LimA group and restored the potency of amphetamine 
      to inhibit uptake. CONCLUSIONS: High-fat bingeing enhanced dopaminergic signaling 
      in the nucleus accumbens by promoting phasic dopamine release and reducing 
      clearance. This study's data show that amphetamine was efficacious in restoring 
      impaired DAT function caused by high-fat bingeing but did not reduce dopamine 
      release to normal. These presynaptic changes should be considered if 
      amphetamine-like dopamine releasers are used as treatments for BED.
CI  - (c) 2021 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The 
      Obesity Society (TOS).
FAU - Jones, Sara R
AU  - Jones SR
AD  - Department of Physiology and Pharmacology, School of Medicine, Wake Forest 
      University, Winston-Salem, North Carolina, USA.
FAU - Fordahl, Steve C
AU  - Fordahl SC
AUID- ORCID: 0000-0002-7093-6774
AD  - Department of Nutrition, UNC Greensboro, Greensboro, North Carolina, USA.
LA  - eng
GR  - R01DA048490/DA/NIDA NIH HHS/United States
GR  - U01 AA014091/AA/NIAAA NIH HHS/United States
GR  - R01 AA023999/AA/NIAAA NIH HHS/United States
GR  - T32 AA007565/AA/NIAAA NIH HHS/United States
GR  - P50AA026117/AA/NIAAA NIH HHS/United States
GR  - R15DK119897/DK/NIDDK NIH HHS/United States
GR  - U01AA014091/AA/NIAAA NIH HHS/United States
GR  - R01 DA048490/DA/NIDA NIH HHS/United States
GR  - P50DA006634/DA/NIDA NIH HHS/United States
GR  - P50 AA026117/AA/NIAAA NIH HHS/United States
GR  - P50 DA006634/DA/NIDA NIH HHS/United States
GR  - T32 DA041349/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20210303
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
RN  - CK833KGX7E (Amphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Amphetamine/pharmacology/*therapeutic use
MH  - Animals
MH  - Binge-Eating Disorder/*blood
MH  - Diet, High-Fat/*adverse effects
MH  - Dopamine/*metabolism
MH  - Male
MH  - Mice
MH  - Nucleus Accumbens/*physiopathology
PMC - PMC8048651
COIS- The authors declared no conflict of interest.
EDAT- 2021/03/05 06:00
MHDA- 2021/06/29 06:00
PMCR- 2021/04/15
CRDT- 2021/03/04 06:04
PHST- 2020/12/15 00:00 [revised]
PHST- 2020/07/06 00:00 [received]
PHST- 2020/12/17 00:00 [accepted]
PHST- 2021/03/05 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2021/03/04 06:04 [entrez]
PHST- 2021/04/15 00:00 [pmc-release]
AID - OBY23122 [pii]
AID - 10.1002/oby.23122 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2021 Apr;29(4):721-730. doi: 10.1002/oby.23122. Epub 
      2021 Mar 3.